

The Bridge to Good Health Care

### Financial Statements for the 2nd quarter of fiscal year ending March 31, 2021 (From Apr. 1, 2020 to Sep. 30, 2020)

## Summary of consolidated results

# JMS Co., Ltd.

Company Code No. 7702

November 6, 2020

# Highlights in Business Results



(unit: JPY million)

	CPULTO			Apr Sep. 2019 Results	Ар	r Sep. Result		Diff.	Year-over-Year
Ne	et s	ales		28,718		2	27,900	(818)	(2.8)%
0	pera	ating prof	fit	817			1,046	228	28.0%
0	Drdinary profit 956			1,127		1,127	171	17.9%	
-		ttributable t of parent	0	637	1,060		1,060	422	66.3%
Ва	isic e	earnings p	er share	JPY 26.14		JPY	43.46		
1		ige Rate	US Dollar	108.63		1	.06.92		
· ·	riod	ge during )	Euro	124.32		1	.19.30	Decreased in sale	es. it (3rd straight year).
	(unit	:: JPY) Sing	apore Dollar	79.34			76.74	increased in prof	it (Siù Straight year).
Sa	Japan	<ul> <li>-Increased sales of Closed Drug Mixing/Infusion System</li> <li>"NEO SHIELD"</li> <li>-Decreased sales of Infusion Sets</li> </ul>			Profit	-Despite the influence of decreased sales and the increase in R&D expense, profit growth due to the influence of the decreased selling cost			
Sales	Overseas	<ul> <li>-Increased sales of Blood bags</li> <li>-Decreased sales of AV Fistula Needles for North</li> </ul>				+	-The subsidy income of extraordinary income resulted in the increase of the profit attributable to owners of parent		
	eas	America				Divid	end foreca	ast -Interim dividend	ividend: JPY 8.5 per share

### Summary by segment (geographical area)



(unit: JPY million)


Singapore Japan Sales incl. Sales incl. internal transaction internal transaction Sales for third party Sales for third party - Profit 10.214 - Profit 9,825 20,425 19,457 1,312 18,923 18,066 Sales Sales Decrease of Increase of 4.7% 4.0% 5,674 664 5,079 544 658 0 Profit Profit 0 Decrease of Decrease of 612 525 14.2% 18.1% 0 O (1) Apr. - Sep. 2019 2020 2019 2020 2019

#### [Sales]

Increased sales of Closed Drug Mixing/Infusion System "NEO SHIELD" were offset by decreased sales of Infusion Sets. reduced net sales.

#### [Ordinary Income]

Despite the decreased selling cost, the influence of decreased sales and the increase in R&D expenses resulted in a reduced profit.



The Bridge to Good Health Care

3

### Summary by segment (geographical area)



Philippines Germany Others Sales incl. Sales incl. internal transaction internal transaction Sales for third party Sales for third party Profit Profit 1,349 1,322 1,561 1,530 2,495 1,560 1,519 Sales Sales Decrease of Increase of 1,978 2.0% 2.0% Profit Profit 119 Improved by Increase of 108 1 0 11 0 21million yen 10.3% 0 56 55 O (18)Apr. - Sep. Apr. - Sep. Apr. - Sep. Apr. - Sep. Apr. - Sep. 2019 2020 2019 2020 2019 2020

#### [Sales]

Increased sales of Apheresis kits for the North America market raised net sales.

#### [Ordinary Income]

The influence of increased sales resulted in an improved profit.

#### [Sales]

Despite the increased sales of AV Fistula Needle, net sales reduced due to influence of foreign currency translation.


[Ordinary Income] The decrease in selling expenses resulted in profit growth.

### (unit: JPY million)


Profit

Sales for third party

Sales




\*This segment includes business activity of domestic subsidiaries, United States, South Korea and Thailand.



### Sales increase or decrease (Customer's Location)






# Selling, General and Admin. Expenses



(unit: JPY million)




	Apr Sep. 2019	Apr Sep. 2020	Diff.	Year -over- Year
Labor Cost	2,953	2,869	(83)	(2.8)%
Transport	842	870	28	3.4%
R & D	742	798	55	7.5%
Depreciation	178	168	(9)	(5.5)%
Others	2,040	1,731	(309)	(15.1)%
Total	6,757	6,439	(318)	(4.7)%

[Others] Travel expenses and Advertising and promotion expenses decreased.

### Ordinary profit : Compared with the previous year





Apr. - Sep. 2019

Apr. - Sep. 2020

## Forecast for FYE Mar. 2021



	(unit: JPY million)						
		FYE Mar. 2020 Result	FYE Mar. 2021 Forecast	Year-over-Year			
Net sales		58,569	59,500	1.6%			
Operating prof	fit	2,314	2,000	(13.6)%			
Ordinary profit	t	2,672	2,200	(17.7)%			
Profit attributable owners of parent	to	1,977	1,600	(19.1)%			
Basic earnings	per share	JPY 81.12	JPY 65.62				
Exchange Rate	US Dollar	108.74	108				
(average during period)	Euro	122.07	120				
(unit: JPY)	Singapore Dollar	79.28	78				

-Obtained import license and launched JMS Tongue Pressure Measuring Device in South Korea. Jul. 2020


- -Launched a new Infusion Pump "CURESENSE IP-100". Sep. 2020
- -Received the "Good Design Award 2020" for three products (Infusion Pump, Tongue Pressure Measuring Device and Centrifugal Blood Pump System). Oct. 2020

-Launched a new Portable Electrocardiograph "myBeat Home ECG". Oct. 2020

The Bridge to Good Health Care 10



JMS Tongue Pressure Measuring Device



myBeat Home ECG







The Bridge to Good Health Care 11



### The Bridge to Good Health Care

The assessment figures described on this report are based on available information at this moment, including uncertain data. Actual results may be different from the figures.